Rivastigmine for dementia associated with Parkinson's disease

Date
2004
Author
Wolters, E
Lane, R
Rosa, MM
Quarg, P
Tekin, S
Emre, M
Aarsland, D
Albanese, A
Byrne, EJ
Deuschl, G
De Deyn, PP
Durif, F
Kulisevsky, J
van Laar, T
Lees, A
Poewe, W
Robillard, A
Metadata
Show full item record
Abstract
Background: Cholinergic deficits are prominent in patients who have dementia associated with Parkinson's disease. We investigated the effects of the dual cholinesterase inhibitor rivastigmine in such patients.
URI
http://hdl.handle.net/20.500.12627/10179
https://doi.org/10.1056/nejmoa041470
Collections